Cancer‐Specific Antihuman Podoplanin Antibody chLpMab ‐2f Exerts Antitumor Effects Against Pleural Mesothelioma
Cancer Science · 2026
DOI: 10.1111/cas.70325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Aito Yoshida und 15 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan. Hauptthemen laut MEDLINE: Membrane Glycoproteins, Mesothelioma, Pleural Neoplasms, Antibodies, Monoclonal. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, University of Tokushima.
Abstract (Originalsprache)
Pleural mesothelioma (PM) is a malignancy with a poor prognosis owing to its resistance to chemotherapy. To develop a novel treatment for PM, podoplanin (PDPN), a transmembrane glycoprotein, has attracted significant attention because it is highly expressed in PM and is used for its diagnosis. We previously reported that NZ‐12, a human chimeric antihuman PDPN antibody, exhibits antitumor effects against human PM cells through antibody‐dependent cellular cytotoxicity (ADCC) and complement‐dependent cytotoxicity (CDC). Additionally, we developed a cancer‐specific monoclonal antibody (CasMab) production technology and produced a mouse‐human chimeric cancer‐specific antihuman PDPN antibody, chLpMab‐2, along with an afucosylated version, chLpMab‐2f, to enhance ADCC activity. This study aimed to evaluate whether chLpMab‐2f exhibits specific antitumor effects against PM in a preclinical model. We demonstrated that chLpMab‐2f recognized the surface PDPN of human PM cell lines and human PM patient tissue but did not react with human normal tissues such as lung and kidney tissues. Furthermore, these antibodies exhibited ADCC and CDC activity against PDPN‐positive PM cells while showing reduced toxicity toward non‐malignant kidney‐derived PDPN‐positive cells, such as HEK‐293FT. Additionally, chLpMab‐2f demonstrated stronger ADCC activity through more efficient NK cell activation in comparison to chLpMab‐2. Moreover, chLpMab‐2f suppressed tumor progression in subcutaneously and intrathoracically transplanted human PM cells in mice. These findings suggest that PDPN‐targeting immunotherapy with chLpMab‐2f generated by CasMab technology could provide an effective treatment for PM with decreased toxicity toward normal tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Department of Clinical Pharmacy Practice Pedagogy, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Departments of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Departments of Community Medicine for Respirology, Hematology and Metabolism, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Community Medicine for Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
ORCID-Profile: Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- University of Tokushima
Zitieren
APA
Yoshida, A., Abe, S., Izumi, T., Itakura, S., Yamada, K., Wada, T., Yamamoto, T., Sato, C., Mitsuhashi, A., Ogino, H., Sato, S., Shinohara, T., Hanibuchi, M., Kaneko, M. K., Kato, Y., & Nishioka, Y. (2026). Cancer‐Specific Antihuman Podoplanin Antibody chLpMab ‐2f Exerts Antitumor Effects Against Pleural Mesothelioma. Cancer Science. https://doi.org/10.1111/cas.70325
Vancouver
Yoshida A, Abe S, Izumi T, Itakura S, Yamada K, Wada T, et al. Cancer‐Specific Antihuman Podoplanin Antibody chLpMab ‐2f Exerts Antitumor Effects Against Pleural Mesothelioma. Cancer Science. 2026. doi:10.1111/cas.70325
BibTeX
@article{Yoshida2026,
author = {Yoshida, Aito and Abe, Shinji and Izumi, Toshihiro and Itakura, Satoshi and Yamada, Keichiro and Wada, Takuya and Yamamoto, Takaaki and Sato, Chiemi and Mitsuhashi, Atsushi and Ogino, Hirokazu and Sato, Seidai and Shinohara, Tsutomu and Hanibuchi, Masaki and Kaneko, Mika K and Kato, Yukinari and Nishioka, Yasuhiko},
title = {Cancer‐Specific Antihuman Podoplanin Antibody chLpMab ‐2f Exerts Antitumor Effects Against Pleural Mesothelioma},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70325}
}
EUVIMED